Showing results (1611-1620 of 1,677) with videos related to

Sort By:
Pageof 168
Emerging Microbes & Infections|June 27, 2024
HLA-mismatched allogeneic adoptive immune therapy in patients with severely immunosuppressed AIDS: a multicenter, open-label, controlled, phase 2a studyTao Yang, Zhiman Xie, Zhe Xu, et al.
Oncotarget|April 1, 2015
Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serumShaohua Li, Hui Li, Xiqin Yang, et al.
Oncotarget|January 13, 2016
Generation and characterization of a tetraspanin CD151/integrin α6β1-binding domain competitively binding monoclonal antibody for inhibition of tumor progression in HCCAi-Wu Ke, Peng-Fei Zhang, Ying-Hao Shen, et al.
Frontiers in Immunology|September 5, 2022
Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphomaHuanxin Zhang, Zhiling Yan, Ying Wang, et al.
Hepatology (Baltimore, Md.)|May 23, 2015
Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transitionZhi-Chao Wang, Qiang Gao, Jie-Yi Shi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 24, 2026
Tumor control probability modeling of stereotactic radiosurgery and fractionated stereotactic radiotherapy for patients with brainstem metastasesJi-Wen Xu, Huan-Huan Wang, Xin-Tian Li, et al.
Hepatology International|April 15, 2026
Phase-specific polarization of peripheral helper T cells influences immunopathology and viral control in HBV infectionXiao-Yu Li, Peng Zhang, Mengmeng Zhu, et al.
The Journal of Clinical Investigation|March 15, 2021
NLRP3 inflammasome induces CD4+ T cell loss in chronically HIV-1-infected patientsChao Zhang, Jin-Wen Song, Hui-Huang Huang, et al.
Nature Materials|February 22, 2022
Multiple mobile excitons manifested as sidebands in quasi-one-dimensional metallic TaSe<sub>3</sub>Junzhang Ma, Simin Nie, Xin Gui, et al.
Eclinicalmedicine|September 2, 2025
Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 studyJunning Cao, Guangliang Chen, Lihua Qiu, et al.
Pageof 168